Inflammatory arthritis

Developing more precise, personalised treatments for inflammatory arthritis and related autoimmune conditions.

Inflammatory arthritis affects millions of people worldwide and can cause lifelong pain, disability and reduced quality of life. Rheumatoid arthritis alone affects around 1% of the global population, and related conditions such as juvenile idiopathic arthritis and Sjögren’s disease can have a profound impact on people of all ages. Despite advances in treatment, many patients still experience ongoing symptoms, and it remains difficult to predict who will respond to a particular therapy.

We are working to transform care through a precision medicine approach. By combining detailed clinical data with analysis of blood and tissue samples, we are identifying biomarkers that can predict disease outcomes and treatment response, while also discovering new targets for therapy. Our researchers use cutting-edge technologies, including single-cell and spatial molecular analysis, to better understand the mechanisms driving disease and accelerate the development of more effective, personalised treatments.

A major strength of our programme is the close integration of laboratory science, clinical trials and patient involvement. Building on Birmingham’s internationally recognised expertise in rheumatology research, we work with NHS, academic and industry partners to develop and test innovative therapies, including novel early-phase clinical trials across rheumatoid arthritis, Sjögren’s disease and childhood arthritis. By matching the right treatment to the right patient, our aim is to improve outcomes, reduce treatment burden and bring effective new therapies to patients more quickly.